Search
AG-858
go.drugbank.com/drugs/DB05502InvestigationalTumor-derived HSP70-peptide complexes used in vaccine preparations have been shown to prime tumor immunity and tumor-specific T cells in animal models. … HSP70 associates with antigenic peptides, transporting them into antigen presenting cells (APC) for processing.
Pomaglumetad methionil
go.drugbank.com/drugs/DB05096InvestigationalFor LY2140023, the active substance, LY404039, is thought to work by reducing the presynaptic release of another neurotransmitter, glutamate, in brain regions where mGlu2/3 receptors are expressed. … Further studies are planned or are ongoing to learn more about the safety and effectiveness, including determining an optimal therapeutic dose for LY2140023.
Actoxumab
go.drugbank.com/drugs/DB16376InvestigationalActoxumab is under investigation in clinical trial NCT01241552 (A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)
Brodalumab
go.drugbank.com/drugs/DB11776ApprovedInvestigationalBrodalumab was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-severe plaque psoriasis. … Brodalumab has been used in trials studying the treatment of Asthma, Psoriasis, Crohn's Disease, Psoriatic Arthritis, and Rheumatoid Arthritis.
Diclofenamide
go.drugbank.com/drugs/DB01144ApprovedA carbonic anhydrase inhibitor that is used in the treatment of glaucoma.
Tetrathiomolybdate
go.drugbank.com/drugs/DB05088InvestigationalTetrathiomolybdate is an oral, small-molecule, anticopper agent that is highly specific for lowering the levels of free copper in serum. … It is also developed for fibrotic disorders based upon the rationale that the fibrotic disease process is dependent upon the availability of free copper in the body.
Categories: Compounds used in a research, industrial, or household settingSynonyms: Tiomolibdate ionLovotibeglogene autotemcel
go.drugbank.com/drugs/DB18680ApprovedInvestigational[A262736,L49256] On December 8, 2023, lovotibeglogene autotemcel was approved by the FDA under the brand name Lyfgenia for the treatment of sickle cell disease (SCD) in patients ages 12 and older who … [L49266] It was approved alongside [exagamglogene autotemcel] (Casgevy), another gene therapy, with the two treatments comprising the first cell-based gene therapies for the treatment of SCD in patients
Polaprezinc
go.drugbank.com/drugs/DB09221InvestigationalPolaprezinc is a chelated form of zinc and L-carnosine. It is a zinc-related medicine approved for the first time in Japan, which has been clinically used to treat gastric ulcers [L1307, L1308]. … A study in 2013 showed that CO-administration of polaprezinc may be effective against small intestine mucosal injury associated with long-term aspirin therapy [A7840].
Saprisartan
go.drugbank.com/drugs/DB01347ExperimentalThe mode of (functional) AT1 receptor antagonism has been characterized as insurmountable/noncompetitive for saprisartan. … Saprisartan is an AT1 receptor antagonist. It is based on medications of losartan's prototypical chemical structure.
Categories: Agents Acting on the Renin-Angiotensin System, Angiotensin II receptor antagonistsLomustine
go.drugbank.com/drugs/DB01206ApprovedInvestigationalAn alkylating agent of value against both hematologic malignancies and solid tumors.
Synonyms: N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea